Treating Alzheimer's disease: Which drugs work well?
Alzheimer?s disease (AD) is the most common form of dementia among older persons in the U.S. Addressing the recent Manhattan Alzheimer?s Disease Conference, Raymond Pratt, MD, senior director, CNS Therapeutic Area, Eisai Medical Research, Teaneck, NJ, said that in the U.S., AD affects approximately 4 million people over 65 years of age. Pratt pointed out that most patients are cared for at home by relatives until the very latest stages of their disease, so therapies to prevent or delay the progression of AD are very important. The 2003 Manhattan Alzheimer?s Disease Conference was sponsored by Nymox Pharmaceutical Corporation.
In celebration of the organization’s recent convention, NCPA released its annual digest report for members, providing a detailed overview of independent community pharmacy.
In a rapidly evolving diabetes and obesity management landscape, Brian Smith, PharmD, discusses approaches that are helping patients maximize their outcomes on GLP-1 therapy.